Arvinas, Inc. (NASDAQ:ARVN) Receives $19.76 Consensus PT from Analysts

Key Points

• Arvinas, Inc. has received an average rating of "Moderate Buy" from 22 research firms, with 12 analysts recommending a buy and 10 advising a hold.
• The current average price target for Arvinas stock is $19.76, with recent target adjustments ranging from $8.00 to $21.00 by various firms.
• Arvinas reported a negative EPS of ($0.84) for the last quarter, slightly exceeding expectations, while revenue fell significantly by 70.7% year-over-year.

Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the twenty-two research firms that are presently covering the firm, Marketbeat Ratings reports. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $19.7632.

ARVN has been the subject of a number of recent analyst reports. Leerink Partnrs cut shares of Arvinas from a "strong-buy" rating to a "hold" rating in a report on Sunday, June 1st. UBS Group cut their target price on shares of Arvinas from $74.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, May 15th. Wells Fargo & Company cut their target price on shares of Arvinas from $19.00 to $16.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Leerink Partners reissued a "market perform" rating and set a $9.00 target price (down previously from $10.00) on shares of Arvinas in a research note on Monday, June 2nd. Finally, Guggenheim decreased their target price on shares of Arvinas from $16.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, August 7th.

Insider Buying and Selling

In other Arvinas news, CFO Andrew Saik sold 5,700 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $7.61, for a total transaction of $43,377.00. Following the transaction, the chief financial officer directly owned 164,401 shares in the company, valued at $1,251,091.61. This represents a 3.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 4.73% of the stock is owned by company insiders.

Institutional Trading of Arvinas

Several hedge funds have recently bought and sold shares of ARVN. Invesco Ltd. grew its stake in shares of Arvinas by 1.6% in the 4th quarter. Invesco Ltd. now owns 37,254 shares of the company's stock worth $714,000 after purchasing an additional 581 shares during the last quarter. Bank of Montreal Can grew its position in Arvinas by 2.7% during the fourth quarter. Bank of Montreal Can now owns 39,407 shares of the company's stock valued at $755,000 after purchasing an additional 1,044 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Arvinas by 3.8% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,514 shares of the company's stock valued at $700,000 after purchasing an additional 1,353 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Arvinas during the fourth quarter valued at approximately $28,000. Finally, LPL Financial LLC grew its position in Arvinas by 12.5% during the fourth quarter. LPL Financial LLC now owns 18,669 shares of the company's stock valued at $358,000 after purchasing an additional 2,077 shares in the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Trading Up 4.5%

Arvinas stock traded up $0.31 during mid-day trading on Friday, hitting $7.10. The stock had a trading volume of 958,121 shares, compared to its average volume of 2,188,215. The firm's 50 day moving average is $7.51 and its 200 day moving average is $9.75. Arvinas has a one year low of $5.90 and a one year high of $29.61. The firm has a market capitalization of $520.90 million, a P/E ratio of -7.02 and a beta of 2.22.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.03. Arvinas had a negative net margin of 19.47% and a negative return on equity of 12.01%. The business had revenue of $22.40 million for the quarter, compared to analyst estimates of $34.42 million. During the same period in the previous year, the company earned ($0.49) earnings per share. The business's revenue for the quarter was down 70.7% on a year-over-year basis. As a group, equities research analysts forecast that Arvinas will post -3.81 earnings per share for the current year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.